TABLE OF CONTENTS
1 INTRODUCTION 18
1.1 OBJECTIVES OF THE STUDY 18
1.2 MARKET DEFINITION 18
1.3 OVERVIEW 18
1.4 CURRENCY AND PRICING 20
1.5 LIMITATIONS 20
1.6 MARKETS COVERED 20
2 MARKET SEGMENTATION 23
2.1 MARKETS COVERED 23
2.2 GEOGRAPHICAL SCOPE 24
2.3 YEARS CONSIDERED FOR THE STUDY 25
2.4 DBMR TRIPOD DATA VALIDATION MODEL 26
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 29
2.6 MULTIVARIATE MODELLING 30
2.7 MARKET APPLICATION COVERAGE GRID 31
2.8 PRODUCT LIFELINE CURVE 32
2.9 DBMR MARKET POSITION GRID 33
2.10 VENDOR SHARE ANALYSIS 34
2.11 SECONDARY SOURCES 35
2.12 ASSUMPTIONS 35
3 EXECUTIVE SUMMARY 36
4 PREMIUM INSIGHTS 38
4.1 PESTEL ANALYSIS 39
4.2 PORTER FIVE FORCES 40
4.3 PATENT ANALYSIS 41
4.4 PATIENT FLOW DIAGRAM 42
4.5 KEY PRICING STRATEGIES 43
4.6 FUTURE THERAPIES 44
4.7 KEY PATIENT ENROLLMENT STRATEGIES 45
5 PIPELINE ANALYSIS 46
6 EPIDEMIOLOGY 47
7 INDUSTRY INSIGHTS 48
8 EUROPE PEMPHIGUS VULGARIS MARKET: REGULATIONS 49
9 MARKET OVERVIEW 52
9.1 DRIVERS 54
9.1.1 EMERGING TREATMENT OPTIONS FOR PEMPHIGUS VULGARIS 54
9.1.2 GROWING SUPPORT OF NGOS FOR THE AFFECTED PATIENTS 54
9.1.3 AWARENESS REGARDING THE DISEASE 55
9.2 RESTRAINTS 55
9.2.1 STRICT REGULATORY GUIDELINES 55
9.2.2 HIGH TREATMENT COSTS 55
9.3 OPPORTUNITIES 56
9.3.1 INCREASING DEMAND FOR PERSONALIZED MEDICINE 56
9.3.2 INCREASING HEALTHCARE FACILITIES 56
9.3.3 DIGITAL HEALTH TECHNOLOGIES FOR TREATMENT MANAGEMENT 57
9.4 CHALLENGES 57
9.4.1 ADVERSE EFFECTS ASSOCIATED WITH MEDICATIONS 57
9.4.2 REIMBURSEMENT AND COVERAGE POLICIES 58
10 EUROPE PEMPHIGUS VULGARIS MARKET, BY DIAGNOSIS AND TREATMENT 59
10.1 OVERVIEW 60
10.2 TREATMENT 63
10.2.1 MEDICATIONS, BY TYPE 63
10.2.1.1 CORTICOSTEROIDS 64
10.2.1.2 STEROID- SPARING IMMUNOSUPPRESSANT DRUGS 64
10.2.1.2.1 AZATHIOPRINE 65
10.2.1.2.2 MYCOPHENALATE MOFETIL 65
10.2.1.2.3 METHOTREXATE 65
10.2.1.2.4 CYCLOPHOSPHAMIDE 65
10.2.1.2.5 MIZORIBINE 65
10.2.1.2.6 OTHERS 65
10.2.1.3 ANTI- INFLAMMATORY AGENTS 65
10.2.1.3.1 DIAMINODYPHENYL SULFONE 66
10.2.1.3.2 TETRACYCLINE 66
10.2.1.3.3 OTHERS 66
10.2.1.4 BIOLOGICS 66
10.2.1.5 INTRAVENOUS IMMUNOGLOBULIN 66
10.2.1.6 ANTIBIOTICS 66
10.2.1.7 ANTIFUNGALS 66
10.2.1.8 ANTIVIRALS 66
10.2.1.9 OTHER MEDICATIONS 66
10.2.2 MEDICATIONS, BY ROUTE OF ADMINISTRATION 66
10.2.2.1 ORAL 67
10.2.2.2 TOPICAL 67
10.2.2.3 PARENTERAL 67
10.2.2.4 OTHERS 67
10.2.3 MEDICATIONS, BY DRUG TYPE 67
10.2.3.1 GENERIC 68
10.2.3.2 BRANDED 68
10.3 DIAGNOSIS 68
10.3.1 SKIN BIOPSY 69
10.3.2 BLOOD TEST 69
10.3.3 ENDOSCOPY 69
11 EUROPE PEMPHIGUS VULGARIS MARKET, BY POPULATION TYPE 70
11.1 OVERVIEW 71
11.2 ADULTS 74
11.3 GERIATRIC 75
11.4 PEDIATRIC 76
12 EUROPE PEMPHIGUS VULGARIS MARKET, BY END USER 77
12.1 OVERVIEW 78
12.2 HOSPITALS 81
12.3 SPECIALTY CLINICS 81
12.4 RESEARCH INSTITUTES 82
12.5 OTHERS 83
13 EUROPE PEMPHIGUS VULGARIS MARKET, BY DISTRIBUTION CHANNEL 84
13.1 OVERVIEW 85
13.2 HOSPITALS PHARMACY 88
13.3 RETAIL PHARMACY 88
13.4 ONLINE PHARMACY 89
14 EUROPE PEMPHIGUS VULGARIS MARKET, BY REGION 90
14.1 EUROPE 91
14.1.1 GERMANY 100
14.1.2 U.K. 104
14.1.3 FRANCE 108
14.1.4 ITALY 112
14.1.5 SPAIN 116
14.1.6 SWITZERLAND 120
14.1.7 TURKEY 124
14.1.8 RUSSIA 128
14.1.9 BELGIUM 132
14.1.10 NETHERLANDS 136
14.1.11 REST OF EUROPE 139
15 EUROPE PEMPHIGUS VULGARIS MARKET, COMPANY LANDSCAPE 140
15.1 COMPANY SHARE ANALYSIS: EUROPE 140
16 SWOT ANALYSIS 141
17 COMPANY PROFILE 142
17.1 ABBVIE INC. 142
17.1.1 COMPANY SNAPSHOT 142
17.1.2 REVENUE ANALYSIS 142
17.1.3 COMPANY SHARE ANALYSIS 143
17.1.4 PRODUCT PORTFOLIO 143
17.1.5 RECENT DEVELOPMENTS 144
17.2 MERCK & CO., INC., 145
17.2.1 COMPANY SNAPSHOT 145
17.2.2 REVENUE ANALYSIS 145
17.2.3 COMPANY SHARE ANALYSIS 146
17.2.4 PRODUCT PORTFOLIO 146
17.2.5 RECENT DEVELOPMENT 146
17.3 SANOFI 147
17.3.1 COMPANY SNAPSHOT 147
17.3.2 REVENUE ANALYSIS 147
17.3.3 COMPANY SHARE ANALYSIS 148
17.3.4 PRODUCT PORTFOLIO 148
17.3.5 RECENT DEVELOPMENT 148
17.4 REGENERON PHARMACEUTICALS INC. 149
17.4.1 COMPANY SNAPSHOT 149
17.4.2 REVENUE ANALYSIS 149
17.4.3 COMPANY SHARE ANALYSIS 150
17.4.4 PRODUCT PORTFOLIO 150
17.4.5 RECENT DEVELOPMENT 150
17.5 NOVARTIS AG 151
17.5.1 COMPANY SNAPSHOT 151
17.5.2 REVENUE ANALYSIS 151
17.5.3 COMPANY SHARE ANALYSIS 152
17.5.4 PRODUCT PORTFOLIO 152
17.5.5 RECENT DEVELOPMENT 152
17.6 AMGEN INC. 153
17.6.1 COMPANY SNAPSHOT 153
17.6.2 REVENUE ANALYSIS 153
17.6.3 PRODUCT PORTFOLIO 154
17.6.4 RECENT DEVELOPMENTS 154
17.7 ASTRAZENECA 155
17.7.1 COMPANY SNAPSHOT 155
17.7.2 REVENUE ANALYSIS 155
17.7.3 COMPANY SHARE ANALYSIS 156
17.7.4 PRODUCT PORTFOLIO 156
17.7.5 RECENT DEVELOPMENTS 157
17.8 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 158
17.8.1 COMPANY SNAPSHOT 158
17.8.2 REVENUE ANALYSIS 158
17.8.3 PRODUCT PORTFOLIO 159
17.8.4 RECENT DEVELOPMENT 159
17.9 CELLTRION HEALTHCARE CO., LTD 160
17.9.1 COMPANY SNAPSHOT 160
17.9.2 REVENUE ANALYSIS 160
17.9.3 PRODUCT PORTFOLIO 161
17.9.4 RECENT DEVELOPMENTS 161
17.10 F. HOFFMANN- LA ROCHE LTD. 162
17.10.1 COMPANY SNAPSHOT 162
17.10.2 REVENUE ANALYSIS 162
17.10.3 PRODUCT PORTFOLIO 163
17.10.4 RECENT DEVELOPMENT 163
17.11 FRESENIUS KABI AG 164
17.11.1 COMPANY SNAPSHOT 164
17.11.2 REVENUE ANALYSIS 164
17.11.3 PRODUCT PORTFOLIO 165
17.11.4 RECENT DEVELOPMENT 165
17.12 GSK PLC 166
17.12.1 COMPANY SNAPSHOT 166
17.12.2 REVENUE ANALYSIS 166
17.12.3 PRODUCT PORTFOLIO 167
17.12.4 RECENT DEVELOPMENT 167
17.13 JOHNSON & JOHNSON SERVICES, INC. 168
17.13.1 COMPANY SNAPSHOT 168
17.13.2 REVENUE ANALYSIS 168
17.13.3 COMPANY SHARE ANALYSIS 169
17.13.4 PRODUCT PORTFOLIO 169
17.13.5 RECENT DEVELOPMENT 169
17.14 LILLY 170
17.14.1 COMPANY SNAPSHOT 170
17.14.2 REVENUE ANALYSIS 170
17.14.3 PRODUCT PORTFOLIO 171
17.14.4 RECENT DEVELOPMENT 171
17.15 PFIZER INC. 172
17.15.1 COMPANY SNAPSHOT 172
17.15.2 REVENUE ANALYSIS 172
17.15.3 PRODUCT PORTFOLIO 173
17.15.4 RECENT DEVELOPMENT 173
17.16 RAKSHIT DRUGS PVT. LTD 174
17.16.1 COMPANY SNAPSHOT 174
17.16.2 PRODUCT PORTFOLIO 174
17.16.3 RECENT DEVELOPMENT 174
17.17 TEVA PHARMACEUTICAL INDUSTRIES LTD 175
17.17.1 COMPANY SNAPSHOT 175
17.17.2 REVENUE ANALYSIS 175
17.17.3 PRODUCT PORTFOLIO 176
17.17.4 RECENT DEVELOPMENT 176
17.18 ZYDUS GROUP 177
17.18.1 COMPANY SNAPSHOT 177
17.18.2 REVENUE ANALYSIS 177
17.18.3 PRODUCT PORTFOLIO 178
17.18.4 RECENT DEVELOPMENT 178
18 QUESTIONNAIRE 179
19 RELATED REPORTS 181

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.